A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

Study acronym: YKAA
StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Dec 2026 → Mar 2027
See other at-risk trials from Eli Lilly

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Dec 2026 to Mar 2027
    • Eligibility criteria expanded, about 15 words
  2. Enrollment target: 132 to 124
    • Eligibility criteria expanded, about 6 words
    v9
  3. 3 versions Re-verified since Sep 2, 2025, no change to tracked fieldsv6-v8
  4. Site details revisedv5
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Aug 2026 to Dec 2026
    • Start date changed from estimate of May 2025 to May 16, 2025
    • Site details revised
    v3
  2. Site contact updatedv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Type 2 Diabetes
2,236 trials monitored
See 113 trials at risk
Type 1 Diabetes
888 trials monitored
See 39 trials at risk
The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4057996 gets into the bloodstream and how long it takes the body to eliminate it. The study will last 11 weeks for Part A1-A2, 4 weeks for A3-A5, 6 weeks for Part B and 7 weeks for Part C, all approximations, excluding a screening period.
Trial Details
NCT Number NCT06945406
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Related terms Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Enrollment 124 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov